AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

09-30 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
29/09/26	€0.6940	+0.87%
25/09/26	€0.6880	-1.99%
24/09/26	€0.7020	-1.40%
23/09/26	€0.7120	-0.14%
22/09/26	€0.7130	-0.56%

Real-time Boerse Muenchen

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Boerse Muenchen 00:43:47 29/09/2026 +04			5-day change	1st Jan Change
0.6940 ^EUR	+0.87%		-3.51%	-50.50%

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement

Market Cap	55.21M 62.77M 52.21M 47.35M 88.93M 6.03B 89.45M 625M 241M 3.07B 236M 231M 9.88B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	55.21M 62.77M 52.21M 47.35M 88.93M 6.03B 89.45M 625M 241M 3.07B 236M 231M 9.88B	EV / Sales 2026 *	46x	EV / Sales 2027 *	42.5x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	AB	Real-time
CBOE	ABp	Real-time
London S.E.	0Q77	Delayed
Tradegate	A8D	Real-time
Boerse Muenchen	A8D	Real-time
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time
Börse Stuttgart	A8D	Delayed

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT
08-10	AB Science raises €14.2m
07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-07	AB Science S.A. Announces Board Changes	CI
07-07	AB Science S.A. Announces CEO Changes	CI
07-03	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Stock Boerse Muenchen

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
08-10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
08-04	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

09-25	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026
08-24	AB Science : Franchissement de seuils et déclaration d'intention
08-17	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
08-17	AB Science procède au règlement-livraison de son placement privé
08-17	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 week	-3.51%
Current month	-1.29%
1 month	-6.90%
3 months	-20.46%
6 months	-41.10%
Current year	-50.50%

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	65	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+0.87%	-3.51%	-45.22%	-70.79%	62.37M
MERCK & CO., INC.	-0.06%	+1.24%	+89.27%	+43.05%	367B
MERCK KGAA	+2.56%	+6.62%	+29.88%	-11.02%	66.89B
HALOZYME THERAPEUTICS, INC.	-0.89%	+0.39%	+53.07%	+193.60%	12.93B
KYOWA KIRIN CO., LTD.	-0.93%	-0.44%	-2.69%	-16.04%	7.54B
SK BIOPHARMACEUTICALS CO., LTD.	+0.40%	-1.93%	-24.93%	-11.60%	4.38B
YUHAN CORPORATION	+0.81%	-1.58%	-34.87%	+3.48%	4.07B
BETTA PHARMACEUTICALS CO., LTD.	-1.08%	+1.04%	-29.63%	-15.59%	3.02B
SUPERNUS PHARMACEUTICALS, INC.	+4.55%	+6.19%	-5.17%	+56.05%	2.48B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.84%	-1.50%	-21.36%	-28.68%	1.91B
Average	+0.53%	-0.28%	+0.84%	+14.25%	52.25B
Weighted average by Cap.	+0.38%	+1.56%	+74.49%	+37.09%

	2026 *	2027 *
Net sales	1.2M 1.36M 1.13M 1.03M 1.93M 131M 1.94M 13.59M 5.25M 66.83M 5.12M 5.01M 215M	1.3M 1.48M 1.23M 1.11M 2.09M 142M 2.11M 14.72M 5.68M 72.4M 5.55M 5.43M 233M
Net income	-	-
Net Debt	-	-

1 week	0.67	0.72
1 month	0.67	0.75
3 years	0.51	4.4
5 years	0.51	13.56